Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
Price:
1.515 USD
2.36%
Market Closed
Updated:
May 7, 2024
Marinus Pharmaceuticals Inc
Cash from Financing Activities
|
Marinus Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Marinus Pharmaceuticals Inc
NASDAQ:MRNS
|
Cash from Financing Activities
$26.6m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$21.4B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$8.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$5.6B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-7%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$2.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Marinus Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
26.6m
USD
26.6m
USD
Based on the financial report for Dec 31, 2023, Marinus Pharmaceuticals Inc's Cash from Financing Activities amounts to 26.6m USD.
What is Marinus Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-9%
-9%
Over the last year, the Cash from Financing Activities growth was -79%. The average annual Cash from Financing Activities growth rates for Marinus Pharmaceuticals Inc have been -38% over the past three years , -9% over the past five years .
You don't have any saved screeners yet
